UniProt ID | RUVB2_HUMAN | |
---|---|---|
UniProt AC | Q9Y230 | |
Protein Name | RuvB-like 2 | |
Gene Name | RUVBL2 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 463 | |
Subcellular Localization | Nucleus matrix. Nucleus, nucleoplasm. Cytoplasm. Membrane. Mainly localized in the nucleus, associated with nuclear matrix or in the nuclear cytosol. Although it is also present in the cytoplasm and associated with the cell membranes. | |
Protein Description | Possesses single-stranded DNA-stimulated ATPase and ATP-dependent DNA helicase (5' to 3') activity; hexamerization is thought to be critical for ATP hydrolysis and adjacent subunits in the ring-like structure contribute to the ATPase activity.; Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a direct role in DNA repair when recruited to sites of DNA damage. Component of a SWR1-like complex that specifically mediates the removal of histone H2A.Z/H2AFZ from the nucleosome.; Proposed core component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair.; Plays an essential role in oncogenic transformation by MYC and also modulates transcriptional activation by the LEF1/TCF1-CTNNB1 complex. May also inhibit the transcriptional activity of ATF2.; Involved in the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway where it negatively regulates expression of ER stress response genes.. | |
Protein Sequence | MATVTATTKVPEIRDVTRIERIGAHSHIRGLGLDDALEPRQASQGMVGQLAARRAAGVVLEMIREGKIAGRAVLIAGQPGTGKTAIAMGMAQALGPDTPFTAIAGSEIFSLEMSKTEALTQAFRRSIGVRIKEETEIIEGEVVEIQIDRPATGTGSKVGKLTLKTTEMETIYDLGTKMIESLTKDKVQAGDVITIDKATGKISKLGRSFTRARDYDAMGSQTKFVQCPDGELQKRKEVVHTVSLHEIDVINSRTQGFLALFSGDTGEIKSEVREQINAKVAEWREEGKAEIIPGVLFIDEVHMLDIESFSFLNRALESDMAPVLIMATNRGITRIRGTSYQSPHGIPIDLLDRLLIVSTTPYSEKDTKQILRIRCEEEDVEMSEDAYTVLTRIGLETSLRYAIQLITAASLVCRKRKGTEVQVDDIKRVYSLFLDESRSTQYMKEYQDAFLFNELKGETMDTS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MATVTATTK ------CCEEEECCC | 15.69 | 25944712 | |
3 | Phosphorylation | -----MATVTATTKV -----CCEEEECCCC | 19.66 | 20068231 | |
5 | Phosphorylation | ---MATVTATTKVPE ---CCEEEECCCCCC | 17.58 | 28857561 | |
7 | Phosphorylation | -MATVTATTKVPEIR -CCEEEECCCCCCHH | 20.13 | 20860994 | |
8 | Phosphorylation | MATVTATTKVPEIRD CCEEEECCCCCCHHC | 27.81 | 30622161 | |
9 | Ubiquitination | ATVTATTKVPEIRDV CEEEECCCCCCHHCC | 51.98 | 21890473 | |
9 | Acetylation | ATVTATTKVPEIRDV CEEEECCCCCCHHCC | 51.98 | 25953088 | |
9 | Sumoylation | ATVTATTKVPEIRDV CEEEECCCCCCHHCC | 51.98 | 28112733 | |
9 | Ubiquitination | ATVTATTKVPEIRDV CEEEECCCCCCHHCC | 51.98 | 21890473 | |
26 | Phosphorylation | IERIGAHSHIRGLGL EEEECCCCCCCCCCC | 21.78 | 20068231 | |
29 | Methylation | IGAHSHIRGLGLDDA ECCCCCCCCCCCCCC | 28.94 | 115493015 | |
46 | Sulfoxidation | PRQASQGMVGQLAAR HHHHCCHHHHHHHHH | 2.07 | 21406390 | |
67 | Methylation | LEMIREGKIAGRAVL HHHHHCCCCCCEEEE | 25.32 | 20603076 | |
81 | Phosphorylation | LIAGQPGTGKTAIAM EEECCCCCCHHHHHH | 42.03 | 21406692 | |
110 | Phosphorylation | IAGSEIFSLEMSKTE ECCCEEEEEECCHHH | 29.13 | - | |
115 | Ubiquitination | IFSLEMSKTEALTQA EEEEECCHHHHHHHH | 49.42 | - | |
119 | Ubiquitination | EMSKTEALTQAFRRS ECCHHHHHHHHHHHH | 2.72 | - | |
132 | Ubiquitination | RSIGVRIKEETEIIE HHHCCEECCCEEEEE | 38.64 | - | |
139 | Ubiquitination | KEETEIIEGEVVEIQ CCCEEEEECEEEEEE | 55.77 | - | |
141 | Ubiquitination | ETEIIEGEVVEIQID CEEEEECEEEEEEEE | 30.51 | - | |
152 | Ubiquitination | IQIDRPATGTGSKVG EEEECCCCCCCCCCE | 37.65 | - | |
157 | 2-Hydroxyisobutyrylation | PATGTGSKVGKLTLK CCCCCCCCCEEEEEE | 57.25 | - | |
160 | Acetylation | GTGSKVGKLTLKTTE CCCCCCEEEEEEECC | 41.09 | 26051181 | |
160 | Ubiquitination | GTGSKVGKLTLKTTE CCCCCCEEEEEEECC | 41.09 | - | |
162 | Phosphorylation | GSKVGKLTLKTTEME CCCCEEEEEEECCCE | 29.69 | 24719451 | |
164 | Ubiquitination | KVGKLTLKTTEMETI CCEEEEEEECCCEEH | 48.44 | 21906983 | |
168 | Sulfoxidation | LTLKTTEMETIYDLG EEEEECCCEEHHHHC | 5.31 | 28183972 | |
170 | Phosphorylation | LKTTEMETIYDLGTK EEECCCEEHHHHCHH | 24.43 | 29978859 | |
172 | Phosphorylation | TTEMETIYDLGTKMI ECCCEEHHHHCHHHH | 16.73 | 28796482 | |
176 | Phosphorylation | ETIYDLGTKMIESLT EEHHHHCHHHHHHHC | 25.41 | 28796482 | |
177 | Ubiquitination | TIYDLGTKMIESLTK EHHHHCHHHHHHHCC | 35.76 | - | |
178 | Ubiquitination | IYDLGTKMIESLTKD HHHHCHHHHHHHCCC | 4.06 | - | |
181 | Phosphorylation | LGTKMIESLTKDKVQ HCHHHHHHHCCCCCC | 30.34 | 26074081 | |
183 | Phosphorylation | TKMIESLTKDKVQAG HHHHHHHCCCCCCCC | 46.61 | 26074081 | |
184 | 2-Hydroxyisobutyrylation | KMIESLTKDKVQAGD HHHHHHCCCCCCCCC | 61.93 | - | |
184 | Ubiquitination | KMIESLTKDKVQAGD HHHHHHCCCCCCCCC | 61.93 | 21906983 | |
186 | 2-Hydroxyisobutyrylation | IESLTKDKVQAGDVI HHHHCCCCCCCCCEE | 37.49 | - | |
186 | Acetylation | IESLTKDKVQAGDVI HHHHCCCCCCCCCEE | 37.49 | 25953088 | |
186 | Ubiquitination | IESLTKDKVQAGDVI HHHHCCCCCCCCCEE | 37.49 | 21906983 | |
189 | Ubiquitination | LTKDKVQAGDVITID HCCCCCCCCCEEEEE | 21.09 | - | |
191 | Ubiquitination | KDKVQAGDVITIDKA CCCCCCCCEEEEECC | 31.49 | - | |
197 | Ubiquitination | GDVITIDKATGKISK CCEEEEECCCCCCHH | 43.95 | 21890473 | |
197 | 2-Hydroxyisobutyrylation | GDVITIDKATGKISK CCEEEEECCCCCCHH | 43.95 | - | |
197 | Acetylation | GDVITIDKATGKISK CCEEEEECCCCCCHH | 43.95 | 25953088 | |
197 | Ubiquitination | GDVITIDKATGKISK CCEEEEECCCCCCHH | 43.95 | 21890473 | |
199 | O-linked_Glycosylation | VITIDKATGKISKLG EEEEECCCCCCHHHC | 44.76 | 30379171 | |
208 | Phosphorylation | KISKLGRSFTRARDY CCHHHCCCCCCCCCC | 29.22 | 28555341 | |
215 | Phosphorylation | SFTRARDYDAMGSQT CCCCCCCCCCCCCCC | 10.47 | 28796482 | |
218 | Sulfoxidation | RARDYDAMGSQTKFV CCCCCCCCCCCCEEE | 4.92 | 30846556 | |
220 | Phosphorylation | RDYDAMGSQTKFVQC CCCCCCCCCCEEEEC | 22.92 | 17525332 | |
222 | Phosphorylation | YDAMGSQTKFVQCPD CCCCCCCCEEEECCC | 28.31 | 21815630 | |
223 | Acetylation | DAMGSQTKFVQCPDG CCCCCCCEEEECCCC | 35.58 | 25953088 | |
223 | Ubiquitination | DAMGSQTKFVQCPDG CCCCCCCEEEECCCC | 35.58 | - | |
224 | Ubiquitination | AMGSQTKFVQCPDGE CCCCCCEEEECCCCH | 5.35 | - | |
234 | Ubiquitination | CPDGELQKRKEVVHT CCCCHHHHCCEEEEE | 77.41 | - | |
234 | 2-Hydroxyisobutyrylation | CPDGELQKRKEVVHT CCCCHHHHCCEEEEE | 77.41 | - | |
234 | Acetylation | CPDGELQKRKEVVHT CCCCHHHHCCEEEEE | 77.41 | 25953088 | |
234 | Ubiquitination | CPDGELQKRKEVVHT CCCCHHHHCCEEEEE | 77.41 | 21906983 | |
236 | 2-Hydroxyisobutyrylation | DGELQKRKEVVHTVS CCHHHHCCEEEEEEE | 62.99 | - | |
236 | Ubiquitination | DGELQKRKEVVHTVS CCHHHHCCEEEEEEE | 62.99 | - | |
241 | Phosphorylation | KRKEVVHTVSLHEID HCCEEEEEEEHHHEE | 10.53 | 30622161 | |
243 | Phosphorylation | KEVVHTVSLHEIDVI CEEEEEEEHHHEEEE | 25.76 | 30622161 | |
252 | Phosphorylation | HEIDVINSRTQGFLA HHEEEEECCCCCEEE | 26.11 | 30622161 | |
254 | Phosphorylation | IDVINSRTQGFLALF EEEEECCCCCEEEEE | 32.63 | 21712546 | |
262 | Phosphorylation | QGFLALFSGDTGEIK CCEEEEECCCCCCCC | 36.29 | 19651622 | |
265 | Phosphorylation | LALFSGDTGEIKSEV EEEECCCCCCCCHHH | 39.99 | 19651622 | |
269 | Sumoylation | SGDTGEIKSEVREQI CCCCCCCCHHHHHHH | 35.94 | - | |
269 | Ubiquitination | SGDTGEIKSEVREQI CCCCCCCCHHHHHHH | 35.94 | 21906983 | |
279 | 2-Hydroxyisobutyrylation | VREQINAKVAEWREE HHHHHHHHHHHHHHH | 37.17 | - | |
279 | Acetylation | VREQINAKVAEWREE HHHHHHHHHHHHHHH | 37.17 | 25038526 | |
279 | Ubiquitination | VREQINAKVAEWREE HHHHHHHHHHHHHHH | 37.17 | 21906983 | |
318 | Phosphorylation | FLNRALESDMAPVLI HHHHHHHCCCCCEEE | 33.27 | - | |
320 | Acetylation | NRALESDMAPVLIMA HHHHHCCCCCEEEEE | 6.72 | - | |
320 | Ubiquitination | NRALESDMAPVLIMA HHHHHCCCCCEEEEE | 6.72 | - | |
320 | Sulfoxidation | NRALESDMAPVLIMA HHHHHCCCCCEEEEE | 6.72 | 21406390 | |
323 | Ubiquitination | LESDMAPVLIMATNR HHCCCCCEEEEEECC | 4.03 | - | |
326 | Sulfoxidation | DMAPVLIMATNRGIT CCCCEEEEEECCCCE | 3.09 | 30846556 | |
328 | Phosphorylation | APVLIMATNRGITRI CCEEEEEECCCCEEE | 14.20 | 20068231 | |
336 | Methylation | NRGITRIRGTSYQSP CCCCEEEECCCCCCC | 38.76 | 115493023 | |
338 | Phosphorylation | GITRIRGTSYQSPHG CCEEEECCCCCCCCC | 17.89 | 28152594 | |
339 | Phosphorylation | ITRIRGTSYQSPHGI CEEEECCCCCCCCCC | 24.81 | 28152594 | |
340 | Phosphorylation | TRIRGTSYQSPHGIP EEEECCCCCCCCCCC | 16.91 | 28152594 | |
342 | Phosphorylation | IRGTSYQSPHGIPID EECCCCCCCCCCCHH | 15.61 | 28152594 | |
353 | Methylation | IPIDLLDRLLIVSTT CCHHHHCCEEEEECC | 31.22 | 115493007 | |
358 | Phosphorylation | LDRLLIVSTTPYSEK HCCEEEEECCCCCCC | 21.41 | 28152594 | |
359 | Phosphorylation | DRLLIVSTTPYSEKD CCEEEEECCCCCCCC | 22.39 | 28152594 | |
360 | Phosphorylation | RLLIVSTTPYSEKDT CEEEEECCCCCCCCH | 16.84 | 21815630 | |
362 | Phosphorylation | LIVSTTPYSEKDTKQ EEEECCCCCCCCHHH | 27.63 | 28152594 | |
363 | Phosphorylation | IVSTTPYSEKDTKQI EEECCCCCCCCHHHH | 39.10 | 28152594 | |
365 | 2-Hydroxyisobutyrylation | STTPYSEKDTKQILR ECCCCCCCCHHHHEE | 65.83 | - | |
365 | Acetylation | STTPYSEKDTKQILR ECCCCCCCCHHHHEE | 65.83 | 23954790 | |
365 | Malonylation | STTPYSEKDTKQILR ECCCCCCCCHHHHEE | 65.83 | 26320211 | |
365 | Ubiquitination | STTPYSEKDTKQILR ECCCCCCCCHHHHEE | 65.83 | 21906983 | |
367 | Phosphorylation | TPYSEKDTKQILRIR CCCCCCCHHHHEEEE | 35.60 | 23312004 | |
368 | 2-Hydroxyisobutyrylation | PYSEKDTKQILRIRC CCCCCCHHHHEEEEE | 45.54 | - | |
368 | Acetylation | PYSEKDTKQILRIRC CCCCCCHHHHEEEEE | 45.54 | 25953088 | |
368 | Malonylation | PYSEKDTKQILRIRC CCCCCCHHHHEEEEE | 45.54 | 26320211 | |
368 | Ubiquitination | PYSEKDTKQILRIRC CCCCCCHHHHEEEEE | 45.54 | - | |
372 | Ubiquitination | KDTKQILRIRCEEED CCHHHHEEEEECHHH | 18.88 | - | |
382 | Acetylation | CEEEDVEMSEDAYTV ECHHHCCCCCCHHHH | 5.51 | - | |
382 | Ubiquitination | CEEEDVEMSEDAYTV ECHHHCCCCCCHHHH | 5.51 | - | |
399 | Ubiquitination | RIGLETSLRYAIQLI HHCHHHHHHHHHHHH | 6.74 | - | |
411 | Ubiquitination | QLITAASLVCRKRKG HHHHHHHHHHHHCCC | 3.46 | - | |
415 | Methylation | AASLVCRKRKGTEVQ HHHHHHHHCCCCEEE | 54.02 | 20137074 | |
417 | Acetylation | SLVCRKRKGTEVQVD HHHHHHCCCCEEEHH | 73.54 | 71283 | |
417 | Ubiquitination | SLVCRKRKGTEVQVD HHHHHHCCCCEEEHH | 73.54 | 21906983 | |
419 | Phosphorylation | VCRKRKGTEVQVDDI HHHHCCCCEEEHHHH | 35.70 | 29255136 | |
427 | Ubiquitination | EVQVDDIKRVYSLFL EEEHHHHHHHHHHHH | 42.69 | 21890473 | |
427 | 2-Hydroxyisobutyrylation | EVQVDDIKRVYSLFL EEEHHHHHHHHHHHH | 42.69 | - | |
427 | Acetylation | EVQVDDIKRVYSLFL EEEHHHHHHHHHHHH | 42.69 | 23954790 | |
427 | Malonylation | EVQVDDIKRVYSLFL EEEHHHHHHHHHHHH | 42.69 | 26320211 | |
427 | Ubiquitination | EVQVDDIKRVYSLFL EEEHHHHHHHHHHHH | 42.69 | 21890473 | |
430 | Nitration | VDDIKRVYSLFLDES HHHHHHHHHHHHCCH | 12.04 | - | |
430 | Phosphorylation | VDDIKRVYSLFLDES HHHHHHHHHHHHCCH | 12.04 | 20090780 | |
431 | Phosphorylation | DDIKRVYSLFLDESR HHHHHHHHHHHCCHH | 15.13 | 28152594 | |
437 | Phosphorylation | YSLFLDESRSTQYMK HHHHHCCHHCHHHHH | 31.06 | 28112733 | |
440 | Phosphorylation | FLDESRSTQYMKEYQ HHCCHHCHHHHHHHH | 23.70 | 21601212 | |
444 | Sumoylation | SRSTQYMKEYQDAFL HHCHHHHHHHHHHHH | 48.62 | 28112733 | |
444 | Ubiquitination | SRSTQYMKEYQDAFL HHCHHHHHHHHHHHH | 48.62 | 21906983 | |
446 | Phosphorylation | STQYMKEYQDAFLFN CHHHHHHHHHHHHHH | 13.23 | 20068231 | |
456 | Sumoylation | AFLFNELKGETMDTS HHHHHHHCCCCCCCC | 48.82 | - | |
456 | Sumoylation | AFLFNELKGETMDTS HHHHHHHCCCCCCCC | 48.82 | 28112733 | |
456 | Ubiquitination | AFLFNELKGETMDTS HHHHHHHCCCCCCCC | 48.82 | 2190698 | |
459 | Phosphorylation | FNELKGETMDTS--- HHHHCCCCCCCC--- | 29.08 | 21712546 | |
460 | Sulfoxidation | NELKGETMDTS---- HHHCCCCCCCC---- | 4.62 | 30846556 | |
462 | Phosphorylation | LKGETMDTS------ HCCCCCCCC------ | 26.05 | 27251275 | |
463 | Phosphorylation | KGETMDTS------- CCCCCCCC------- | 33.68 | 27251275 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of RUVB2_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of RUVB2_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of RUVB2_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"ATM and ATR substrate analysis reveals extensive protein networksresponsive to DNA damage."; Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.; Science 316:1160-1166(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-220, AND MASSSPECTROMETRY. |